Suppr超能文献

纳米药物引爆溶酶体炸弹。

Nanodrugs Detonate Lysosome Bombs.

作者信息

Xiang Yuting, Li Niansheng, Liu Min, Chen Qiaohui, Long Xingyu, Yang Yuqi, Xiao Zuoxiu, Huang Jia, Wang Xiaoyuan, Yang Yunrong, Zhang Jinping, Liu Chong, Huang Qiong

机构信息

Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, China.

Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, China.

出版信息

Front Pharmacol. 2022 May 17;13:909504. doi: 10.3389/fphar.2022.909504. eCollection 2022.

Abstract

Cancer cell lysosomes contain various hydrolases and non-degraded substrates that are corrosive enough to destroy cancer cells. However, many traditional small molecule drugs targeting lysosomes have strong side effects because they cannot effectively differentiate between normal and cancer cells. Most lysosome-based research has focused on inducing mild lysosomal membrane permeabilization (LMP) to release anticancer drugs from lysosomal traps into the cancer cell cytoplasm. In fact, lysosomes are particularly powerful "bombs". Achieving cancer cell-selective LMP induction may yield high-efficiency anticancer effects and extremely low side effects. Nanodrugs have diverse and combinable properties and can be specifically designed to selectively induce LMP in cancer cells by taking advantage of the differences between cancer cells and normal cells. Although nanodrugs-induced LMP has made great progress recently, related reviews remain rare. Herein, we first comprehensively summarize the advances in nanodrugs-induced LMP. Next, we describe the different nanodrugs-induced LMP strategies, namely nanoparticles aggregation-induced LMP, chemodynamic therapy (CDT)-induced LMP, and magnetic field-induced LMP. Finally, we analyze the prospect of nanodrugs-induced LMP and the challenges to overcome. We believe this review provides a unique perspective and inspiration for designing lysosome-targeting drugs.

摘要

癌细胞溶酶体含有多种水解酶和未降解的底物,其腐蚀性足以破坏癌细胞。然而,许多传统的靶向溶酶体的小分子药物具有很强的副作用,因为它们无法有效区分正常细胞和癌细胞。大多数基于溶酶体的研究都集中在诱导轻度溶酶体膜通透性增加(LMP),以将抗癌药物从溶酶体陷阱释放到癌细胞细胞质中。事实上,溶酶体是特别强大的“炸弹”。实现癌细胞选择性LMP诱导可能产生高效的抗癌效果和极低的副作用。纳米药物具有多样且可组合的特性,可以通过利用癌细胞与正常细胞之间的差异进行专门设计,以选择性地诱导癌细胞中的LMP。尽管纳米药物诱导的LMP最近取得了很大进展,但相关综述仍然很少。在此,我们首先全面总结纳米药物诱导LMP的进展。接下来,我们描述不同的纳米药物诱导LMP策略,即纳米颗粒聚集诱导LMP、化学动力学疗法(CDT)诱导LMP和磁场诱导LMP。最后,我们分析纳米药物诱导LMP的前景以及需要克服的挑战。我们相信这篇综述为设计靶向溶酶体的药物提供了独特的视角和灵感。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/321d/9152002/a3a609622403/fphar-13-909504-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验